“Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s260. doi:10.25251/skin.7.supp.260.